ClinicalTrials.gg
Active, not recruitingNCT04869280Updated Jul 21, 2026

Post-Marketing Study of Prucalopride Safety In Pregnancy

An observational study in Chronic Idiopathic Constipation (CIC), sponsored by Takeda. Active, not recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Takeda · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 29 studies in Constipation by Takeda — none open to participants now, 2 under way, none of them phase 3. Constipation · Takeda.

Started
2021
with 1 other
Observational
2 of 29
none open now
Registered
28th of 29
by date

Among the 29 studies in Constipation by Takeda, this one is one of 2 that started in 2021, is one of 2 observational ones, and was the 28th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

None of the 29 studies in Constipation by Takeda is open now. The open studies under Constipation, anywhere →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Constipation by Takeda as a file.
02

Study summary

This study collects information on pregnant women with ongoing constipation who took prucalopride and those who did not take prucalopride. The main aim of the study is to learn if any medical problems in pregnant women or their infants might be related to taking prucalopride during pregnancy.

Participants are not required to take prucalopride during the study. The study is non-interventional. Women and their infants are followed during pregnancy and for 1 year after pregnancy to collect information on maternal, pregnancy, and infant outcomes.

During the study, participants will be asked questions during 3 telephone interviews; 2 during pregnancy and 1 just after their expected delivery date. Participants who took or are taking prucalopride will be asked more detailed questions about this during these interviews. All information is collected remotely, and no visits to the study site are required.

Also, all participants will be asked to complete a questionnaire about their baby when their baby is about 1 year old.

03

Conditions studied

  • Chronic Idiopathic Constipation (CIC)

Browse trials for

Keywords

  • Fetal and infant outcomes
  • Prucalopride
  • Pregnancy Registry
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women from the United States (US) and Canada who have or have not been treated with prucalopride for CIC or IBS-C during their pregnancy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort 1: Prucalopride-Exposed (MOTEGRITY, RESOTRAN) Cohort:

  • Pregnant women.
  • Exposure to MOTEGRITY or RESOTRAN (generic forms of prucalopride not allowed) for the treatment of chronic idiopathic constipation (CIC) or irritable bowel syndrome-constipation (IBS-C), for any number of days, at any dose, and at any time from the 1st day of the LMP up to and including the 12th week after the first day of the LMP. If the date of LMP is unclear, or if a first-trimester ultrasound has been done and the estimated date of conception is more than one week discrepant from the menstrual period calculation, the first-trimester ultrasound-derived date will be used to calculate a date for LMP and conception.
  • Agree to the conditions and requirements of the study including the interview schedule, and release of medical records.

Cohort 2: Disease-Matched Comparison Cohort:

  • Pregnant women.
  • Diagnosed with CIC or IBS-C; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible.
  • Agree to the conditions and requirements of the study including the interview schedule, and release of medical records.

Exclusion criteria

Exclusion Criteria:

Cohort 1: Prucalopride-Exposed (MOTEGRITY, RESOTRAN) Cohort

  • Women who have first contact with the project after prenatal diagnosis of any major structural defect.
  • Women who have enrolled in the prucalopride cohort study with a previous pregnancy (women may only enroll once in the Prucalopride Pregnancy Cohort Study).
  • Women who have used prucalopride for an indication other than CIC or IBS-C.
  • Women who do not have exposure in the first trimester of pregnancy.
  • Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment).
  • Results of a diagnostic test are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.

Cohort 2: Disease-Matched Comparison Cohort:

  • Women who have first contact with the project after prenatal diagnosis of any major structural defect.
  • Exposure to prucalopride (brand name or generic) anytime during the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy.
  • Women who have enrolled in the prucalopride cohort study with a previous pregnancy (women may only enroll once in the Prucalopride Pregnancy Cohort Study).
  • Retrospective enrollment after the outcome of pregnancy is known (i.e. the pregnancy has ended prior to enrollment).
  • Results of a diagnostic test are positive for a major structural defect prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate a major structural defect.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort-1: Pregnant Women Exposed to Prucalopride Prior to Enrollment

    Pregnant women diagnosed with chronic idiopathic constipation (CIC) or irritable bowel syndrome-constipation (IBS-C) who have been exposed to prucalopride during pregnancy and prior to enrollment will be observed.

    Other: No Intervention

  • Cohort-2: Pregnant Women Not Exposed to Prucalopride

    Pregnant women diagnosed with CIC or IBS-C who have not been exposed to prucalopride will be observed.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    This is a non-interventional study.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Major Structural Defects

    Major structural defects are defined and classified using the US Centers for Disease Control and Prevention (CDC) coding manual that is used for the Metropolitan Atlanta Congenital Defects Program (MACDP) classification of major structural defects. All major structural defects will be adjudicated by the co-investigator on this study.

    Time frame: Up to 1 year of age

Secondary outcomes

  1. Number of Participants With Spontaneous Abortion/Miscarriage

    Spontaneous abortion/miscarriage is defined as non-deliberate fetal death that occurs prior to 20 weeks post-LMP.

    Time frame: 20 weeks post-last menstrual period (LMP)

  2. Number of Participants With Stillbirth

    Stillbirth is defined as non-deliberate fetal death anytime in gestation at or after 20 weeks post-LMP.

    Time frame: From 20 weeks post-LMP to end of pregnancy

  3. Number of Participants With Elective Termination/Abortion

    Elective termination/abortion is defined as deliberate termination of pregnancy through medication or surgical procedures. Elective abortions are classified for medical or social reasons.

    Time frame: At the end of pregnancy or through 9-month pregnancy period

  4. Number of Participants With Premature Delivery

    Premature delivery is defined as live birth prior to 37 weeks gestation as counted from LMP (or calculated from first-trimester ultrasound-derived due date if LMP uncertain or more than 1 week discrepant). Elective caesarian deliveries or inductions prior to 37 completed weeks will be considered separately.

    Time frame: Through 9-month pregnancy period

  5. Incidence of Small for Gestational Age

    Small for gestational age is defined as birth size (weight, length or head circumference) less than the 10th centile for sex and gestational age using standard pediatric CDC growth curves for full term or preterm infants.

    Time frame: At birth

  6. Number of Participants With Postnatal Growth Deficiency

    Postnatal growth deficiency is defined as postnatal size (weight, length or head circumference) less than the 10th centile for sex and age using National Center for Health Statistics (NCHS) pediatric growth curves, and adjusted postnatal age for premature infants if the postnatal measurement is obtained at less than 1 year of age.

    Time frame: Up to 1 year of age

  7. Screening for Neurodevelopmental Milestones

    Screening for neurodevelopment performed using the Ages and Stages Questionnaire (ASQ). An abnormal score is defined in the scoring guidelines.

    Time frame: 1 year of age

  8. Incidence of Hospitalization in Live Born Children

    Hospitalizations is defined as any hospitalization of the infant within the first year of life after discharge following delivery.

    Time frame: Up to 1 year of age

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Feb 2027, 68 months after the start.

Of 52 observational studies under Constipation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 68 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2021
First posted
May 3, 2021
StartActual
May 21, 2021
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04869280
Lead sponsor
Takeda
Collaborators
The Organization of Teratology Information Specialists
Responsible party
Sponsor
First posted
May 3, 2021
Start date
May 21, 2021
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Study Director
study director · Takeda
Study Director
study director · The Organization of Teratology Information Specialists

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion